This company listing is no longer active
UCB (UCB N) Stock Overview
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
UCB N Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
UCB SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1,692.27 |
| 52 Week High | €1,861.24 |
| 52 Week Low | €1,692.27 |
| Beta | 0.33 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -28.40% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -21.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| UCB N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -4.8% | -2.1% |
| 1Y | -28.4% | -0.4% | -2.0% |
Return vs Industry: UCB N underperformed the MX Pharmaceuticals industry which returned -15% over the past year.
Return vs Market: UCB N underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| UCB N volatility | |
|---|---|
| UCB N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in MX Market | 5.8% |
| 10% least volatile stocks in MX Market | 2.6% |
Stable Share Price: UCB N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine UCB N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 8,406 | Jean-Christophe Tellier | www.ucb.com |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus.
UCB SA Fundamentals Summary
| UCB N fundamental statistics | |
|---|---|
| Market cap | Mex$322.25b |
| Earnings (TTM) | Mex$8.35b |
| Revenue (TTM) | Mex$108.23b |
Is UCB N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UCB N income statement (TTM) | |
|---|---|
| Revenue | €5.45b |
| Cost of Revenue | €1.67b |
| Gross Profit | €3.77b |
| Other Expenses | €3.35b |
| Earnings | €420.00m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.22 |
| Gross Margin | 69.27% |
| Net Profit Margin | 7.71% |
| Debt/Equity Ratio | 30.5% |
How did UCB N perform over the long term?
See historical performance and comparisonDividends
Does UCB N pay a reliable dividends?
See UCB N dividend history and benchmarks| UCB dividend dates | |
|---|---|
| Ex Dividend Date | Apr 28 2023 |
| Dividend Pay Date | May 03 2023 |
| Days until Ex dividend | 818 days |
| Days until Dividend pay date | 813 days |
Does UCB N pay a reliable dividends?
See UCB N dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/28 20:12 |
| End of Day Share Price | 2023/01/29 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
UCB SA is covered by 55 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark van der Geest | ABN AMRO Bank N.V. |
| Kamla Singh | AlphaValue |
| Charles Pitman | Barclays |